Forecast

Autologous hematopoietic stem cell transplantation (aHSCT) appears to be the most effective treatment against multiple sclerosis in the study.

After more than two years, 75% -83% of patients are without disease progression (vgl. https://link.springer.com/article/10.1007/s00277-015-2337-8). In some patients, the already existing symptoms have improved.

I contacted about 20 patients who were already in Moscow for stem cell transplantation. All report that the disease has stopped. Many report that some symptoms have improved. Everyone would do it again. Some did not regret having done it before.

 

Not allowed in Germany?

The Ethics Committee opposes the treatment because of the mortality rate of 2-6%. Although the medicines currently used in MS are similarly risky with sometimes more than 20% mortality (see https://www.kvberlin.de/40presse/30kvblatt/2011/12/40_medizinthema/kvbs.pdf), but there is a lack of studies that directly compare stem cell transplantation with drug therapy. In Hamburg, there was a start to such a study, funded by the health insurance companies, who have quite an interest in their MS patients are “cured”. The expense, however, broke the budget and the study was discontinued. Of course, the pharmaceutical companies, which like to finance studies, are not interested in such a study because there are no more products to market afterwards.

In Switzerland, stem cell transplantation in MS has been paid since July 2018 in the form of a registry study by the health insurance companies. But even here hard selection conditions and the number of participants and the duration are limited.

Further stem cell transplantations in MS are e.g. in Canada, Sweden, Mexico, Israel, Colerado, China